secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001193125-22-072011
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics eliminates VP Finance role; appoints Gregory Tourangeau as principal accounting officer
--------------------------------------------------------------------------------

- Effective March 11, 2022, Peter Thomson terminated as principal accounting officer due to elimination of VP Finance & Accounting position.
- Mr. Thomson remains employed in a transitional capacity through April 1, 2022.
- Gregory Tourangeau, currently Controller, appointed as principal accounting officer effective March 11, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522072011/0001193125-22-072011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522072011/d306646d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-072011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer